Debbie's Dream Foundation to Fund Two Research Grants
Together, The Young Fellowship Grant and The Career Development Award total $200,000
FT. LAUDERDALE, Fla., Nov. 16, 2015 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF), an international non-profit organization that raises awareness and funds for stomach cancer, launched two research grants totaling $200,000 for the 2015-2016 grant cycle. A Career Development Award for $150,000 and a Young Fellowship Grant for $50,000 are included in the grants offered.
The grants will be administered by the American Association for Cancer Research (AACR), and DDF is pleased to partner with them once again for this opportunity to fund important fellowship and career development awards. The DDF Gastric Cancer Fellowship Grant is geared toward postdoctoral and clinical researchers, while the Career Development Award is geared toward junior faculty who have completed their most recent doctoral degree or medical residency within the past eleven years. Both grants aim to involve those who conduct gastric cancer research and want to establish a successful career path in this field.
"For the third year in a row, we are thrilled to fund gastric cancer research. Each year we have doubled the amount award and the total we have authorized for research is $350,000," said DDF President and Founder Debbie Zelman. "These grants incentivize young bright minds into the field of gastric cancer research which moves us closer to our ultimate goal of making the cure for stomach cancer a reality."
The grants are for basic, translational, and clinical research in stomach cancer and are available to scientists and clinicians at various career levels. Through research, DDF is advancing the fight against stomach cancer to make progress toward the goal of increasing survival and treatment options available for stomach cancer patients. Researchers can find more information about the grants on the Debbie's Dream website at https://www.debbiesdream.org/portal/research-grants.
Stomach cancer is estimated to be the fourth most common cancer worldwide and the second leading cause of death. Eighty percent of stomach cancer patients are diagnosed at stage IV, and those who are diagnosed with stage IV have a 4% chance of being alive in 5 years.
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.
